How does Lutathera work to treat gastroenteropancreatic neuroendocrine tumors?
Medically reviewed by Drugs.com. Last updated on Feb 26, 2020.
Lutathera (lutetium Lu 177 dotatate), a Lu-177-labeled somatostatin analogue, is a radioactive drug that binds to a somatostatin receptor on the gastroenteropancreatic neuroendocrine tumor to exert its cancer-killing effect.
The FDA approved Lutathera for the treatment of somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs) in January 2018. GEP-NETs are rare cancers that form in the pancreas, stomach, intestines, colon and rectum.
- Lutathera Information for Consumers
- Lutathera Information for Healthcare Professionals (includes dosage details)
- Side Effects of Lutathera (detailed)